Nektar Therapeutics  

(Public, NASDAQ:NKTR)   Watch this stock  
Find more results for Schering-Plough Corporation´┐Ż
12.33
+0.16 (1.31%)
Jul 30 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 11.74 - 12.37
52 week 9.51 - 17.53
Open 12.08
Vol / Avg. 1.10M/2.18M
Mkt cap 1.60B
P/E 71.10
Div/yield     -
EPS 0.17
Shares 131.53M
Beta 1.52
Inst. own 98%
Aug 5, 2015
Q2 2015 Nektar Therapeutics Earnings Call - 5:00PM EDT - Add to calendar
Aug 5, 2015
Q2 2015 Nektar Therapeutics Earnings Release - 4:00PM EDT - Add to calendar
Jun 16, 2015
Nektar Therapeutics Annual Shareholders Meeting
Jun 2, 2015
Nektar Therapeutics at Jefferies Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin 31.08% -26.86%
Operating margin 39.56% -8.21%
EBITD margin - -1.77%
Return on average assets 28.84% -12.31%
Return on average equity 238.75% -
Employees 438 -
CDP Score - -

Address

455 Mission Bay Blvd S
SAN FRANCISCO, CA 94158-2158
United States - Map
+1-415-4825300 (Phone)
+1-415-3395300 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Nektar Therapeutics is a clinical-stage biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. The Company’s pipeline is comprised of drug candidates for therapeutic areas, including oncology, pain, anti-infectives, and immunology. The Company’s research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. Its polymer chemistry platform is being used to create specialized therapeutics, including small molecule oral and parenteral drugs, proteins, peptides and antibody fragments.

Officers and directors

Robert B. Chess Independent Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Howard W. Robin President, Chief Executive Officer, Director
Age: 62
Bio & Compensation  - Reuters
John Nicholson Chief Financial Officer, Senior Vice President
Age: 63
Bio & Compensation  - Reuters
Jillian B. Thomsen Senior Vice President - Finance, Chief Accounting Officer
Age: 49
Bio & Compensation  - Reuters
Stephen K. Doberstein Ph.D. Senior Vice President, Chief Scientific Officer
Age: 56
Bio & Compensation  - Reuters
Gilbert M. Labrucherie J.D. Senior Vice President, General Counsel, Secretary
Age: 42
Bio & Compensation  - Reuters
Ivan P. Gergel M.D. Senior Vice President - Drug Development & Chief Medical Officer
Age: 54
Bio & Compensation  - Reuters
Maninder Hora Ph.D. Senior Vice President - Pharmaceutical Development and Manufacturing Operations
Age: 61
Bio & Compensation  - Reuters
R. Scott Greer Independent Director
Age: 56
Bio & Compensation  - Reuters
Joseph J. Krivulka Independent Director
Age: 63
Bio & Compensation  - Reuters